Full Press Release Details
Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study.
IMMP
Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study
Key Takeaway: Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study
Price reaction · baseline $2.13 (2023-05-26 close) · 5 other IMMP headline(s) in the window, move may be shared
day 0 close · peak
-5.6%
day 1
-2.8%
day 3
+2.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)